Literature DB >> 12643016

Current therapies in ovarian cancer.

Abbie L Fields1, Carolyn D Runowicz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12643016     DOI： 10.1081/cnv-120016409

Source DB:  PubMed          Journal:  Cancer Invest        ISSN： 0735-7907            Impact factor:   2.176


× No keyword cloud information.
  5 in total

Review 1.  Intraperitoneal chemotherapy for ovarian cancer.

Authors:  Gregory Friberg; Gini Fleming
Journal:  Curr Oncol Rep       Date:  2003-11       Impact factor: 5.075

2.  Diversities within genotypes, bioactivity and biosynthetic genes of endophytic actinomycetes isolated from three pharmaceutical plants.

Authors:  Yingying Wu; Chunhua Lu; Xiaoming Qian; Yaojian Huang; Yuemao Shen
Journal:  Curr Microbiol       Date:  2009-08-06       Impact factor: 2.188

3.  Human GM3 Synthase Attenuates Taxol-Triggered Apoptosis Associated with Downregulation of Caspase-3 in Ovarian Cancer Cells.

Authors:  Su Huang; Khadijeh Bijangi-Vishehsaraei; Mohammad Reza Saadatzadeh; Ahmad R Safa
Journal:  J Cancer Ther       Date:  2012-10

4.  Human beta-galactoside alpha-2,3-sialyltransferase (ST3Gal III) attenuated Taxol-induced apoptosis in ovarian cancer cells by downregulating caspase-8 activity.

Authors:  Su Huang; Travis W Day; Mi-Ran Choi; Ahmad R Safa
Journal:  Mol Cell Biochem       Date:  2009-05-05       Impact factor: 3.396

5.  Targeting HPV-infected cervical cancer cells with PEGylated liposomes encapsulating siRNA and the role of siRNA complexation with polyethylenimine.

Authors:  Rachel M Levine; Christina V Dinh; Michael A Harris; Efrosini Kokkoli
Journal:  Bioeng Transl Med       Date:  2016-08-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.